Newco Aptadir Therapeutics Srl raised €40 million (US$45.3 million) in a seed round to take forward a new class of RNA ...
In a further sign that nothing is slowing down for the antibody-drug conjugate (ADC) space, Astrazeneca plc agreed to make a ...
The latest phase I/II hurdle for Uniqure NV with ifezuntirgene inilparvovec (ifez-inil) in Huntington’s disease (HD) led to ...
Pan-RAS inhibitor Rasonque (daraxonrasib, Revolution Medicines Inc.) produced a 60% reduction in the risk of death compared ...
China’s medtech sector seems to be an emerging threat to the Western companies. After all, it has already become a global ...
Tolerance Bio Inc. struck its second major licensing deal in six weeks, acquiring global development rights and ex-Japan commercialization rights to Tanabe Pharma Corp.’s clinical-stage ...
Menopause has long been linked to a higher risk of cognitive decline and Alzheimer’s disease (AD) later in life, but the ...
Iregene Therapeutics Co. Ltd. has obtained clinical trial clearances in China and the U.S. for its investigational induced ...
CSPC Pharmaceutical Group Ltd. has obtained clinical trial approval from China’s National Medical Products Administration ...
Currus Biologics Pty Ltd. has obtained IND approval from the FDA for its lead program, CUR-001. Currus will conduct a ...
Jiangsu Hengrui Pharmaceuticals Co. Ltd. has entered into a license agreement with Novo Nordisk A/S for HRS-1596, a ...
Novo Nordisk is shelling out $300 million up front in a potential $2.6 billion deal with Hengrui Pharma to gain exclusive rights to HRS-1596, a phase I-ready glucagon-like peptide-1 receptor and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results